

# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of:  
Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 13-Jun-2023

Revision Number 1

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

### 1.1. Product identifier

**Product Code(s)** CAT 1060  
**Product Name** Olanzapine  
**Form** Not applicable

*NOTE [8] - No registration number is given for this substance because it is under the threshold in REACH Article 6(1) and not subject to the registration requirements according to REACH Title II*

**EC No (EU Index No)** 603-618-4  
**CAS No.** 132539-06-1  
**Chemical name** Olanzapine  
**Pure substance/mixture** Substance  
**Formula** C<sub>17</sub> H<sub>20</sub> N<sub>4</sub> S  
**Molecular weight** 312.43

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

**Recommended use** Laboratory use  
**Uses advised against** No information available

### 1.3. Details of the supplier of the safety data sheet

#### Supplier

British Pharmacopoeia Commission  
MHRA  
10 South Colonnade  
Canary Wharf  
London E14 4PU  
United Kingdom

Tel : +44 (0)20 3080 6561  
eMail: bpcrs@mhra.gov.uk

# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of:  
Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 13-Jun-2023

Revision Number 1

## CAT 1060 - Olanzapine

For further information, please contact

E-mail address bpcrs@mhra.gov.uk

### 1.4. Emergency telephone number

Emergency Telephone +44 (0)20 3080 6561 (Monday - Friday: 8am - 5pm)

Emergency Telephone - §45 - (EC)1272/2008	
Europe	112
Austria	No information available
Bulgaria	
Croatia	
Cyprus	
Czech Republic	
Denmark	
France	
Hungary	
Ireland	
Italy	
Lithuania	
Luxembourg	
Netherlands	
Norway	
Portugal	
Romania	
Slovakia	
Slovenia	
Spain	
Sweden	
Switzerland	

## SECTION 2: Hazards identification

### 2.1. Classification of the substance or mixture

Classification according to  
Regulation (EC) No. 1272/2008 [CLP]

Acute toxicity - Oral	Category 3 - (H301)
Serious eye damage/eye irritation	Category 2 - (H319)

# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of:  
Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 13-Jun-2023

Revision Number 1

## CAT 1060 - Olanzapine

Skin sensitisation	Category 1 - (H317)
Specific target organ toxicity — single exposure	Category 3 - (H336)
Specific target organ toxicity — repeated exposure	Category 2 - (H373)
Chronic aquatic toxicity	Category 4 - (H413)

### 2.2. Label elements

Contains Olanzapine



**Signal word**  
Danger

### Hazard statements

H301 - Toxic if swallowed  
H317 - May cause an allergic skin reaction  
H319 - Causes serious eye irritation  
H336 - May cause drowsiness or dizziness  
H373 - May cause damage to organs through prolonged or repeated exposure  
H413 - May cause long lasting harmful effects to aquatic life

### Precautionary Statements - EU (§28, 1272/2008)

P260 - Do not breathe dust/fume/gas/mist/vapours/spray  
P264 - Wash face, hands and any exposed skin thoroughly after handling  
P280 - Wear protective gloves and eye/face protection  
P301 + P310 - IF SWALLOWED: Immediately call a POISON CENTER or doctor  
P501 - Dispose of contents/ container to an approved waste disposal plant

### 2.3. Other hazards

This substance does not meet the PBT/vPvB criteria of REACH, annex XIII.

**Endocrine Disruptor Information** This product does not contain any known or suspected endocrine disruptors.

Chemical name	EU - REACH (1907/2006) - Article 59(1) - Candidate List of Substances of Very	EU - REACH (1907/2006) - Endocrine Disruptor Assessment List of
---------------	--	--

# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of:  
Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 13-Jun-2023

Revision Number 1

CAT 1060 - Olanzapine

	High Concern (SVHC) for Authorisation	Substances
Olanzapine	-	-

## SECTION 3: Composition/information on ingredients

### 3.1 Substances

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Olanzapine 132539-06-1	90 - 100%	-	603-618-4	Acute Tox. 3 (H301) Eye Irrit. 2 (H319) Skin Sens. 1 (H317) STOT SE 3 (H336) STOT RE 2 (H373) Aquatic Chronic 4 (H413)			

**Full text of H- and EUH-phrases: see section 16**

Acute Toxicity Estimate  
No information available

This product does not contain candidate substances of very high concern at a concentration  $\geq 0.1\%$  (Regulation (EC) No. 1907/2006 (REACH), Article 59)

## SECTION 4: First aid measures

### 4.1. Description of first aid measures

<b>General advice</b>	Show this safety data sheet to the doctor in attendance.
<b>Inhalation</b>	Remove to fresh air. IF exposed or concerned: Get medical advice/attention.
<b>Eye contact</b>	Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Keep eye wide open while rinsing. Do not rub affected area. Get medical attention if irritation develops and persists.

# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of:  
Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 13-Jun-2023

Revision Number 1

CAT 1060 - Olanzapine

<b>Skin contact</b>	Wash with soap and water. May cause an allergic skin reaction. In the case of skin irritation or allergic reactions see a doctor.
<b>Ingestion</b>	Do NOT induce vomiting. Rinse mouth. Never give anything by mouth to an unconscious person. Get medical attention.
<b>Self-protection of the first aider</b>	Avoid contact with skin, eyes or clothing. Wear personal protective clothing (see section 8).

## 4.2. Most important symptoms and effects, both acute and delayed

<b>Symptoms</b>	May cause redness and tearing of the eyes. Burning sensation. Inhalation of high vapour concentrations may cause symptoms like headache, dizziness, tiredness, nausea and vomiting. Itching. Rashes. Hives.
-----------------	---

## 4.3. Indication of any immediate medical attention and special treatment needed

<b>Note to doctors</b>	May cause sensitisation in susceptible persons. Treat symptomatically.
------------------------	--

## **SECTION 5: Firefighting measures**

### 5.1. Extinguishing media

<b>Suitable Extinguishing Media</b>	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
-------------------------------------	---

<b>Large Fire</b>	CAUTION: Use of water spray when fighting fire may be inefficient.
-------------------	--

<b>Unsuitable extinguishing media</b>	Do not scatter spilled material with high pressure water streams.
---------------------------------------	---

### 5.2. Special hazards arising from the substance or mixture

<b>Specific hazards arising from the chemical</b>	Product is or contains a sensitiser. May cause sensitisation by skin contact.
---	---

### 5.3. Advice for firefighters

<b>Special protective equipment and precautions for fire-fighters</b>	Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.
---	--

## **SECTION 6: Accidental release measures**

# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of:  
Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 13-Jun-2023

Revision Number 1

CAT 1060 - Olanzapine

## 6.1. Personal precautions, protective equipment and emergency procedures

<b>Personal precautions</b>	Avoid contact with skin, eyes or clothing. Ensure adequate ventilation. Use personal protective equipment as required. Evacuate personnel to safe areas. Keep people away from and upwind of spill/leak.
<b>Other information</b>	Refer to protective measures listed in Sections 7 and 8.
<b>For emergency responders</b>	Use personal protection recommended in Section 8.

## 6.2. Environmental precautions

<b>Environmental precautions</b>	See Section 12 for additional Ecological Information.
----------------------------------	---

## 6.3. Methods and material for containment and cleaning up

<b>Methods for containment</b>	Prevent further leakage or spillage if safe to do so.
<b>Methods for cleaning up</b>	Take up mechanically, placing in appropriate containers for disposal.
<b>Prevention of secondary hazards</b>	Clean contaminated objects and areas thoroughly observing environmental regulations.

## 6.4. Reference to other sections

<b>Reference to other sections</b>	See section 8 for more information. See section 13 for more information.
------------------------------------	--

## SECTION 7: Handling and storage

### 7.1. Precautions for safe handling

<b>Advice on safe handling</b>	Handle in accordance with good industrial hygiene and safety practice. Ensure adequate ventilation. In case of insufficient ventilation, wear suitable respiratory equipment. Avoid breathing vapours or mists. Avoid contact with skin, eyes or clothing. Do not eat, drink or smoke when using this product. Take off contaminated clothing and wash it before reuse.
<b>General hygiene considerations</b>	Avoid contact with skin, eyes or clothing. Do not eat, drink or smoke when using this product. Wash hands before breaks and after work. Wear suitable gloves and eye/face protection.

### 7.2. Conditions for safe storage, including any incompatibilities

<b>Storage Conditions</b>	Please refer to the manufacturer's certificate for specific storage and transport temperature
---------------------------	---

# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of:  
Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 13-Jun-2023

Revision Number 1

CAT 1060 - Olanzapine

conditions. Store only in the original receptacle unless other advice is given on the CoA. Keep containers tightly closed in a dry, cool and well-ventilated place. Keep out of the reach of children.

## 7.3. Specific end use(s)

**Risk Management Methods (RMM)** The information required is contained in this Safety Data Sheet.

## SECTION 8: Exposure controls/personal protection

### 8.1. Control parameters

**Exposure Limits** This product, as supplied, does not contain any hazardous materials with occupational exposure limits established by the region specific regulatory bodies.

#### Biological occupational exposure limits

This product, as supplied, does not contain any hazardous materials with biological limits established by the region specific regulatory bodies

**Derived No Effect Level (DNEL)** No information available.

**Predicted No Effect Concentration (PNEC)** No information available.

### 8.2. Exposure controls

#### Personal protective equipment

**Eye/face protection** Avoid contact with eyes. Wear safety glasses with side shields (or goggles). If splashes are likely to occur, wear safety glasses with side-shields.

**Hand protection** The protective gloves to be used must comply with the specifications of EC Directive 89/686/EEC and the related standard EN374. Wear protective butyl rubber gloves. Wear suitable gloves.

**Skin and body protection** Wear suitable protective clothing.

# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of:  
Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 13-Jun-2023

Revision Number 1

CAT 1060 - Olanzapine

<b>Respiratory protection</b>	No protective equipment is needed under normal use conditions. If exposure limits are exceeded or irritation is experienced, ventilation and evacuation may be required.
<b>General hygiene considerations</b>	Avoid contact with skin, eyes or clothing. Do not eat, drink or smoke when using this product. Wash hands before breaks and after work. Wear suitable gloves and eye/face protection.
<b>Environmental exposure controls</b>	Do not allow into any sewer, on the ground or into any body of water.

## SECTION 9: Physical and chemical properties

### 9.1. Information on basic physical and chemical properties

<b>Physical state</b>	Solid
<b>Appearance</b>	Crystalline
<b>Colour</b>	light yellow
<b>Odour</b>	Odourless.
<b>Odour threshold</b>	No information available

<u>Property</u>	<u>Values</u>	<u>Remarks • Method</u>
<b>Melting point / freezing point</b>	189 - 195 °C	None known
<b>Initial boiling point and boiling range</b>	No data available	None known
<b>Flammability</b>	No data available	None known
<b>Flammability Limit in Air</b>		None known
<b>Upper flammability or explosive limits</b>	No data available	
<b>Lower flammability or explosive limits</b>	No data available	
<b>Flash point</b>	No data available	None known
<b>Autoignition temperature</b>	No data available	None known
<b>Decomposition temperature</b>		None known
<b>pH</b>	No data available	None known
<b>pH (as aqueous solution)</b>	No data available	No information available
<b>Kinematic viscosity</b>	No data available	None known
<b>Dynamic viscosity</b>	No data available	None known
<b>Water solubility</b>	No data available	None known
<b>Solubility(ies)</b>	No data available	None known
<b>Partition coefficient</b>	No data available	None known
<b>Vapour pressure</b>	No data available	None known
<b>Relative density</b>	1.32	None known
<b>Bulk density</b>	No data available	



# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of:  
Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 13-Jun-2023

Revision Number 1

## CAT 1060 - Olanzapine

Liquid Density	No data available	
Relative vapour density	No data available	None known
Particle characteristics		
Particle Size	No information available	
Particle Size Distribution	No information available	

### 9.2. Other information

Molecular weight	312.43
Molecular formula	C <sub>17</sub> H <sub>20</sub> N <sub>4</sub> S

9.2.1. Information with regards to physical hazard classes  
Not applicable

9.2.2. Other safety characteristics  
No information available

## SECTION 10: Stability and reactivity

### 10.1. Reactivity

Reactivity	No information available.
------------	---------------------------

### 10.2. Chemical stability

Stability	Stable under normal conditions.
-----------	---------------------------------

#### Explosion data

Sensitivity to mechanical impact None.

Sensitivity to static discharge None.

### 10.3. Possibility of hazardous reactions

Possibility of hazardous reactions	None under normal processing.
------------------------------------	-------------------------------

### 10.4. Conditions to avoid

Conditions to avoid	None known based on information supplied.
---------------------	---

### 10.5. Incompatible materials

Incompatible materials	None known based on information supplied.
------------------------	---

Hazardous decomposition products None known based on information supplied.

# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of:  
Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 13-Jun-2023

Revision Number 1

CAT 1060 - Olanzapine

## SECTION 11: Toxicological information

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

#### Information on likely routes of exposure

##### Product Information

Inhalation	Specific test data for the substance or mixture is not available. May cause irritation of respiratory tract. May cause drowsiness or dizziness.
Eye contact	Specific test data for the substance or mixture is not available. Causes serious eye irritation. (based on components). May cause redness, itching, and pain.
Skin contact	Specific test data for the substance or mixture is not available. May cause irritation. Prolonged contact may cause redness and irritation. May cause sensitisation by skin contact. Repeated or prolonged skin contact may cause allergic reactions with susceptible persons. (based on components).
Ingestion	Specific test data for the substance or mixture is not available. Ingestion may cause gastrointestinal irritation, nausea, vomiting and diarrhoea. Toxic if swallowed. (based on components).

#### Symptoms related to the physical, chemical and toxicological characteristics

Symptoms	May cause redness and tearing of the eyes. Inhalation of high vapour concentrations may cause symptoms like headache, dizziness, tiredness, nausea and vomiting. Itching. Rashes. Hives.
----------	--

#### Numerical measures of toxicity

##### Acute toxicity

#### Delayed and immediate effects as well as chronic effects from short and long-term exposure

# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of:  
Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 13-Jun-2023

Revision Number 1

## CAT 1060 - Olanzapine

Skin corrosion/irritation	May cause skin irritation.
Serious eye damage/eye irritation	Classification based on data available for ingredients. Causes serious eye irritation.
Respiratory or skin sensitisation	May cause an allergic skin reaction.
Germ cell mutagenicity	No information available.
Carcinogenicity	No information available.
Reproductive toxicity	No information available.
STOT - single exposure	May cause drowsiness or dizziness.
STOT - repeated exposure	May cause damage to organs through prolonged or repeated exposure.
Aspiration hazard	No information available.

### 11.2. Information on other hazards

#### 11.2.1. Endocrine disrupting properties

Endocrine disrupting properties No information available.

#### 11.2.2. Other information

Other adverse effects No information available.

## SECTION 12: Ecological information

### 12.1. Toxicity

# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of:  
Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 13-Jun-2023

Revision Number 1

## CAT 1060 - Olanzapine

**Ecotoxicity** May cause long lasting harmful effects to aquatic life.

### 12.2. Persistence and degradability

**Persistence and degradability** No information available.

### 12.3. Bioaccumulative potential

**Bioaccumulation** No information available.

Chemical name	Partition coefficient
Olanzapine	4.09

### 12.4. Mobility in soil

**Mobility in soil** No information available.

### 12.5. Results of PBT and vPvB assessment

**PBT and vPvB assessment** No information available.

### 12.6. Endocrine disrupting properties

**Endocrine disrupting properties** No information available.

### 12.7. Other adverse effects

No information available.

## SECTION 13: Disposal considerations

### 13.1. Waste treatment methods

**Waste from residues/unused products** Dispose of in accordance with local regulations. Dispose of waste in accordance with environmental legislation.

**Contaminated packaging** Do not reuse empty containers.

# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of:  
Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 13-Jun-2023

Revision Number 1

CAT 1060 - Olanzapine

## SECTION 14: Transport information

### IATA

14.1 UN number or ID number	UN2811
14.2 UN proper shipping name	Toxic solid, organic, n.o.s. (Olanzapine)
14.3 Transport hazard class(es)	6.1
14.4 Packing group	III
Description	UN2811, Toxic solid, organic, n.o.s. (Olanzapine), 6.1, III
14.5 Environmental hazards	Not applicable
14.6 Special precautions for user	
Special Provisions	A3, A5
ERG Code	6L

### IMDG

14.1 UN number or ID number	UN2811
14.2 UN proper shipping name	Toxic solid, organic, n.o.s. (Olanzapine)
14.3 Transport hazard class(es)	6.1
14.4 Packing group	III
Description	UN2811, Toxic solid, organic, n.o.s. (Olanzapine), 6.1, III
14.5 Marine pollutant	NP
14.6 Special precautions for user	
Special Provisions	223, 274
EmS-No.	F-A, S-A No information available
14.7 Maritime transport in bulk according to IMO instruments	No information available

### RID

14.1 UN number or ID number	UN2811
14.2 UN proper shipping name	Toxic solid, organic, n.o.s. (Olanzapine)
14.3 Transport hazard class(es)	6.1
14.4 Packing group	III
Description	UN2811, Toxic solid, organic, n.o.s. (Olanzapine), 6.1, III
14.5 Environmental hazards	Not applicable
14.6 Special precautions for user	
Special Provisions	274, 614
Classification code	T2

### ADR

14.1 UN number or ID number	UN2811
14.2 UN proper shipping name	Toxic solid, organic, n.o.s. (Olanzapine)
14.3 Transport hazard class(es)	6.1
14.4 Packing group	III
Description	UN2811, Toxic solid, organic, n.o.s. (Olanzapine), 6.1, III, (E)

# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of:  
Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 13-Jun-2023

Revision Number 1

CAT 1060 - Olanzapine

14.5 Environmental hazards	Not applicable
14.6 Special precautions for user	
Special Provisions	274, 614
Classification code	T2
Tunnel restriction code	(E)

## SECTION 15: Regulatory information

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

#### National regulations

##### Germany

Water hazard class (WGK) obviously hazardous to water (WGK 2)

##### Poland

SDS created according to the following Polish regulation: Act of February 25, 2011 on chemical substances and their mixtures (Journal of Laws of 2018, item 143, as amended). Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH), establishing the European Chemicals Agency (EC) as amended. Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labeling and packaging of substances and mixtures, as amended. Regulation of the Minister of Health of 10 August 2012 on the criteria and method of classifying chemical substances and their mixtures (Journal of Laws of 2012, item 1018). Regulation of the Minister of Health of 20 April 2012 on labeling packaging of hazardous substances and mixtures and some mixtures (Journal of Laws of 2012, item 445). Regulation of the Minister of Family, Labor and Social Policy of 12 June 2018 on the maximum allowable concentrations and intensities of factors harmful to health in the work environment (Journal of Laws of 2018, item 1286). Announcement of the Minister of Economy, Labor and Social Policy of August 28, 2003 on the publication of the unified text of the Ordinance of the Minister of Labor and Social Policy on general health and safety at work regulations (Journal of Laws of 2003, No. 169, item 1650). Regulation of the Minister of Health of 30 December 2004 on occupational safety and health related to the presence of chemical agents in the workplace (Journal of Laws of 2005, No. 11, item 86). Act of December 14, 2012 on waste (Journal of Laws of 2013, item 21) Regulation of the Minister of Health of December 30, 2004 on occupational health and safety related to the presence of chemical agents in the workplace (Journal U. of 2005, No. 11, item 86). Waste Act of December 14, 2012 (Journal of Laws of 2013, item 21). Act of 13 June 2013 on the

# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of:  
Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 13-Jun-2023

Revision Number 1

CAT 1060 - Olanzapine

management of packaging and packaging waste, Journal of Laws 2013, item 888).  
Government statement of September 24, 2002 - European Agreement on the  
International Carriage of Dangerous Goods by Road (ADR) (Journal of Laws No. 194,  
item 1629 and Journal of Laws of 2003, No. 207, item 2013 and 2014).

## European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

## Authorisations and/or restrictions on use:

This product does not contain substances subject to authorisation (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

## DIRECTIVE (EU) 2021/1187 on the marketing and use of explosives precursors

Not applicable

## Persistent Organic Pollutants

Not applicable

## Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

## International Inventories

### TSCA

Complies under research and development exemption or is regulated by a different government agency.

### DSL/NDSL

Contact supplier for inventory compliance status

### EINECS/ELINCS

Contact supplier for inventory compliance status

### ENCS

Contact supplier for inventory compliance status

### IECSC

Contact supplier for inventory compliance status

### KECL

Contact supplier for inventory compliance status

### PICCS

Contact supplier for inventory compliance status

### AIIC

Contact supplier for inventory compliance status

## Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**DSL/NDSL** - Canadian Domestic Substances List/Non-Domestic Substances List

# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of:  
Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 13-Jun-2023

Revision Number 1

CAT 1060 - Olanzapine

**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances  
**ENCS** - Japan Existing and New Chemical Substances  
**IECSC** - China Inventory of Existing Chemical Substances  
**KECL** - Korean Existing and Evaluated Chemical Substances  
**PICCS** - Philippines Inventory of Chemicals and Chemical Substances  
**AICS** - Australian Inventory of Chemical Substances

## 15.2. Chemical safety assessment

### Chemical Safety Report

A Chemical Safety Assessment is not required for this substance

## SECTION 16: Other information

### Key or legend to abbreviations and acronyms used in the safety data sheet

#### Full text of H-Statements referred to under section 3

H301 - Toxic if swallowed  
H317 - May cause an allergic skin reaction  
H319 - Causes serious eye irritation  
H336 - May cause drowsiness or dizziness  
H373 - May cause damage to organs through prolonged or repeated exposure  
H413 - May cause long lasting harmful effects to aquatic life

#### Legend

SVHC: Substances of Very High Concern for Authorisation:

#### Legend Section 8: Exposure controls/personal protection

TWA TWA (time-weighted average) STEL STEL (Short Term Exposure Limit)  
Ceiling Maximum limit value Sk\* Skin designation

Classification procedure	
Classification according to Regulation (EC) No. 1272/2008 [CLP]	Method Used
Acute oral toxicity	Calculation method
Acute dermal toxicity	Calculation method
Acute inhalation toxicity - gas	Calculation method
Acute inhalation toxicity - Vapour	Calculation method
Acute inhalation toxicity - dust/mist	Calculation method
Skin corrosion/irritation	Calculation method
Serious eye damage/eye irritation	Calculation method
Respiratory sensitisation	Calculation method



# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of:  
Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 13-Jun-2023

Revision Number 1

## CAT 1060 - Olanzapine

Skin sensitisation	Calculation method
Mutagenicity	Calculation method
Carcinogenicity	Calculation method
Reproductive toxicity	Calculation method
STOT - single exposure	Calculation method
STOT - repeated exposure	Calculation method
Acute aquatic toxicity	Calculation method
Chronic aquatic toxicity	Calculation method
Aspiration hazard	Calculation method
Ozone	Calculation method

### Key literature references and sources for data used to compile the SDS

Agency for Toxic Substances and Disease Registry (ATSDR)  
U.S. Environmental Protection Agency ChemView Database  
European Food Safety Authority (EFSA)  
EPA (Environmental Protection Agency)  
Acute Exposure Guideline Level(s) (AEGL(s))  
U.S. Environmental Protection Agency Federal Insecticide, Fungicide, and Rodenticide Act  
U.S. Environmental Protection Agency High Production Volume Chemicals  
Food Research Journal  
Hazardous Substance Database  
International Uniform Chemical Information Database (IUCLID)  
Japan GHS Classification  
Australian National Industrial Chemicals Notification and Assessment Scheme (NICNAS)  
NIOSH (National Institute for Occupational Safety and Health)  
National Library of Medicine's ChemID Plus (NLM CIP)  
National Library of Medicine's PubMed database (NLM PUBMED)  
National Toxicology Program (NTP)  
New Zealand's Chemical Classification and Information Database (CCID)  
Organisation for Economic Co-operation and Development Environment, Health, and Safety Publications  
Organisation for Economic Co-operation and Development High Production Volume Chemicals Programme  
Organisation for Economic Co-operation and Development Screening Information Data Set  
World Health Organization

Revision date 13-Jun-2023

This material safety data sheet complies with the requirements of Regulation (EC) No. 1907/2006

### Disclaimer

The information in this safety data sheet (SDS) has been prepared with due care and is true and accurate to the best of our knowledge. The user must determine the suitability of the information for its particular purpose, ensure compliance with existing laws and regulations, and be aware that other or additional safety or performance considerations may arise when using, handling and/ or storing the material. The information in this SDS does not purport to be all inclusive or a guarantee as to the properties of the material supplied, and should be used only as a guide. British Pharmacopoeia

## SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of:  
Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 13-Jun-2023

Revision Number 1

CAT 1060 - Olanzapine

---

Commission Office makes no warranties or representations as to the accuracy and completeness of the information contained herein, shall not be held responsible for the suitability of this information for the user's intended purposes or the consequences of such use, and shall not be liable for any damage or loss, howsoever arising, direct or otherwise.

**End of Safety Data Sheet**